Mentioned in ?
References in periodicals archive ?
The Company's lead product candidates included MT 100, a proprietary formulation containing metoclopramide hydrochloride and naproxen sodium; MT 300, a proprietary formulation of dihydroergotamine mesylate in a pre-filled syringe, and MT 400, which is being developed as a co-active acute migraine therapy.
MT 100 is a combination of two approved drugs, naproxen sodium and metoclopramide hydrochloride, in a sequential release formulation.
The Company's lead product candidates during the Class Period were MT-100, a proprietary formulation containing metoclopramide hydrochloride and naproxen sodium, and MT-300, a pre-filled syringe containing dihydroergotamine mesylate, or DHE.